Advertisement

Related Videos

Opening Session Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Apr
19
Today In Oncology
Melanoma Can AI Enable Diagnosis Prediction
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
Romiplostim for Chemotherapy-Induced Thrombocytopenia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo